Fisetin in Mild Alzheimer's Disease — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Fisetin in Mild Alzheimer's Disease — Stella

Home/Alzheimer s Disease/

View on ClinicalTrials.gov

Recruiting

Back to Alzheimer s Disease trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

Canada

Sunnybrook Research Institute, Toronto, Ontario

Key details

Phase

Safety & dosing

Sponsor

Sunnybrook Health Sciences Centre

Collaborators

Sunnybrook Research Institute

Enrollment target

~5 participants

Started

January 2026

Primary completion

November 2026

Age range

60 Years and older

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.